Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



An Open Label, Expanded Access Protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Multiple Cancer Types

Neuroblastoma (Pediatrics), Pediatric Solid Tumors
N/A
Kitko, Carrie
NCT01590680
VICCPED1249

KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL / AML / MDS Allo-HCT Children

Multiple Cancer Types

This is a phase II, open-label, non-randomized, prospective study of haploidentical transplantation using KIR-favorable donors for children with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT). The relationship of KIR2DL1 polymorphisms to survival in children with these diseases undergoing any approach to allogeneic HCT during the study time frame will also be determined.
Myelodysplastic Syndrome, Pediatric Leukemia, Pediatrics
II
Kitko, Carrie
NCT02646839
VICCPED1711

Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant

Multiple Cancer Types

This randomized phase III trial studies how well Lactobacillus plantarum works in preventing acute graft versus host disease in children undergoing donor stem cell transplant. Lactobacillus plantarum may help prevent the development of gastrointestinal graft versus host disease in children, adolescents, and young adults undergoing donor stem cell transplant.
Gastrointestinal, Pediatrics
III
Kitko, Carrie
NCT03057054
COGACCL1633

Identifying Predictors of Poor Health-Related Quality-of-Life among Pediatric Hematopoietic Stem Cell Donors.

Pediatrics

Pediatrics
N/A
Kitko, Carrie
NCT03718546
VICCPED1949

Mount Sinai Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository

Miscellaneous

Miscellaneous
N/A
Kitko, Carrie
VICCPED1544

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed / Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed / Refractory B-Cell Non-Hodgkin Lymphoma

Pediatric Leukemia

The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed / refractory (r / r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r / r) B-cell non-Hodgkin lymphoma (NHL).
Pediatric Leukemia
I/II
Kitko, Carrie
NCT02625480
VICCPED15143

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

Multiple Cancer Types

The purpose of the study is to assess the efficacy and safety of tisagenlecleucel in children and adolescents with relapsed / refractory B-cell non-Hodgkin lymphoma (r / r B-NHL). For pediatric patients who have r / r B-NHL, survival rates are dismal, only ~20-50% subjects are alive at 2 years with overall response rate (ORR) of 20-30% after conventional salvage chemotherapy.
Pediatric Lymphoma, Pediatrics
II
Kitko, Carrie
NCT03610724
VICCPED18169

A Phase 1 / 2 Study to Evaluate SNDX- 6352 in Subjects With Active cGVHD

Multiple Cancer Types

This is a Phase 1 / 2, Open-label, Dose Escalation study to investigate SNDX-6352 in subjects with active cGVHD.
Hematologic, Phase I
I
Kitko, Carrie
NCT03604692
VICCCTTP18109

Itacitinib in Treating Patients with Low Risk Graft Versus Host Disease

Hematologic

This phase II trial studies how well itacitinib works in treating patients with low risk graft versus host disease. Graft versus host disease is the most common serious complication after bone marrow transplant. It occurs when donor immune cells (the graft) attack normal tissue in the recipient’s body. This inflammatory immune system attack can damage the skin, liver, stomach, and / or intestines. Itacitinib may help reduce the inflammation associated with graft versus host disease by blocking the enzymes associated with activating the inflammatory process.
Hematologic
II
Kitko, Carrie
NCT03846479
VICCPED1912

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Hematologic

This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of KD025 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least 2 prior lines of systemic therapy
Hematologic
II
Kitko, Carrie
NCT03640481
VICCCTT18121

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: